Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.
DrugsSep 1, 2026 (epub)
John A Hey, Susan Abushakra, Aidan Power et al.
✦ AI-curated · Sources linked
In 30 seconds
This study analyzed plasma biomarkers in APOE4 homozygotes with early Alzheimer's disease from Phase 3 and Phase 2 trials of valiltramiprosate/ALZ-801. The randomized controlled trial showed significant reductions in plasma p-tau217 and p-tau217/Aβ42, with a 36% decrease in p-tau217 in the MCI subgroup compared to placebo. These changes correlated with clinical and neuroimaging improvements.
Key findings
- Valiltramiprosate reduced plasma p-tau217 by 36% in MCI subjects compared to a 17% increase with placebo.
- In the Phase 3 MCI subgroup, p-tau217/Aβ42 ratio decreased by 40% with valiltramiprosate.
- Plasma NfL was significantly lower with valiltramiprosate than placebo at week 78 in MCI subjects.
- Reductions in p-tau217 correlated with improvements in ADAS-Cog13 and hippocampal volume.
Why it matters
The findings suggest that valiltramiprosate may modify disease progression in early Alzheimer's disease, particularly in APOE4 carriers. Understanding biomarker responses can help clinicians assess treatment efficacy and tailor interventions for patients at high genetic risk.